S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
NASDAQ:SPRB

Spruce Biosciences (SPRB) Stock Price, News & Analysis

$0.74
-0.03 (-3.92%)
(As of 04/12/2024 ET)
Today's Range
$0.73
$0.77
50-Day Range
$0.70
$5.49
52-Week Range
$0.68
$5.95
Volume
521,794 shs
Average Volume
1.74 million shs
Market Capitalization
$30.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67

Spruce Biosciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
669.7% Upside
$5.67 Price Target
Short Interest
Healthy
1.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Spruce Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2.61 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.33) to ($1.16) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.35 out of 5 stars

Medical Sector

271st out of 926 stocks

Pharmaceutical Preparations Industry

117th out of 419 stocks

SPRB stock logo

About Spruce Biosciences Stock (NASDAQ:SPRB)

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

SPRB Stock Price History

SPRB Stock News Headlines

My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
Stocks to Watch: Spruce Biosciences, UiPath
Why Is Spruce Biosciences (SPRB) Stock Down 78% Today?
See More Headlines
Receive SPRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2024
Today
4/14/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SPRB
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.67
High Stock Price Target
$10.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+669.7%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$-47,920,000.00
Net Margins
-474.96%
Pretax Margin
-474.96%

Debt

Sales & Book Value

Annual Sales
$10.09 million
Book Value
$1.88 per share

Miscellaneous

Free Float
38,725,000
Market Cap
$30.29 million
Optionable
Optionable
Beta
2.52
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Michael G. Grey (Age 71)
    Executive Chairman
    Comp: $70k
  • Dr. Javier Szwarcberg M.D. (Age 54)
    M.P.H., CEO & Director
    Comp: $693.9k
  • Mr. Samir M. Gharib CPA (Age 42)
    M.B.A., President & CFO
    Comp: $536.13k
  • Dr. Ralph William Charlton III (Age 54)
    M.D., Chief Medical Officer
    Comp: $436.38k
  • Ms. P. J. Ramtin
    Senior Vice President of Business Operations
  • Ms. Heidi Petersen M.P.H.
    Senior Vice President of Regulatory & Quality

SPRB Stock Analysis - Frequently Asked Questions

Should I buy or sell Spruce Biosciences stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SPRB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRB, but not buy additional shares or sell existing shares.
View SPRB analyst ratings
or view top-rated stocks.

What is Spruce Biosciences' stock price target for 2024?

8 Wall Street research analysts have issued 12-month target prices for Spruce Biosciences' shares. Their SPRB share price targets range from $2.00 to $10.00. On average, they predict the company's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 669.7% from the stock's current price.
View analysts price targets for SPRB
or view top-rated stocks among Wall Street analysts.

How have SPRB shares performed in 2024?

Spruce Biosciences' stock was trading at $2.93 on January 1st, 2024. Since then, SPRB shares have decreased by 74.9% and is now trading at $0.7362.
View the best growth stocks for 2024 here
.

Are investors shorting Spruce Biosciences?

Spruce Biosciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 320,400 shares, an increase of 69.3% from the March 15th total of 189,300 shares. Based on an average daily trading volume, of 1,230,000 shares, the short-interest ratio is currently 0.3 days. Currently, 1.5% of the shares of the company are short sold.
View Spruce Biosciences' Short Interest
.

When is Spruce Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our SPRB earnings forecast
.

How were Spruce Biosciences' earnings last quarter?

Spruce Biosciences, Inc. (NASDAQ:SPRB) released its earnings results on Wednesday, March, 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.18. The company had revenue of $2.89 million for the quarter, compared to analysts' expectations of $1.65 million. Spruce Biosciences had a negative trailing twelve-month return on equity of 52.31% and a negative net margin of 474.96%.

When did Spruce Biosciences IPO?

Spruce Biosciences (SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO.

How do I buy shares of Spruce Biosciences?

Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SPRB) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners